1303585-26-3

Basic information

• Product Name: 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide
• Synonyms: 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide
• CAS NO: 1303585-26-3
• Molecular Weight: 434.442
• Mol File: 1303585-26-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide(1303585-26-3)
• EPA Substance Registry System: 8-methyl-N-(4-methylthiazol-2-yl)-6-(3-(trifluoromethyl)phenyl)-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxamide(1303585-26-3)

Safety Data

• Hazardous Substances Data: 1303585-26-3(Hazardous Substances Data)

Upstream product

• 1303587-94-1 6-bromo-8-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1303587-92-9 3-acetoxy-4-methylpyridine-1-oxide 
• 943994-62-5 6-bromo-8-methyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one 
• 1303587-93-0 6-bromo-4-methyl-2-nitropyridin-3-ol 
• 943994-61-4 ethyl [(6-bromo-4-methyl-2-nitropyridin-3-yl)oxy]acetate 
• 1121-19-3 4-methylpyridin-3-ol 
• 15128-89-9 2-nitro-3-hydroxy-4-methylpyridine 
• 1603-91-4 4-methylthiazol-2-ylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1303587-95-2 8-methyl-6-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine 
• 1003-67-4 4-methylpyridine-1-oxide 

Relevant articles and documents

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.